The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Medically reviewed by Danielle Weiss, MD Diabetic macular edema (DME) is a leading cause of vision loss in people with ...

UBX] has announced top-line results from the Phase IIb ASPIRE clinical trial of intravitreal UBX1325 (foselutoclax) in ...

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

Surrozen (SRZN) announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ...

Blindness or vision loss is a growing concern among older adults, and one of the leading causes is a condition known as ...

HC Wainwright raised their FY2025 EPS estimates for shares of Opthea in a note issued to investors on Tuesday, March 25th. HC ...

Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Opthea in a report issued on Monday, ...